Hubert Fernandez, MD, Cleveland Clinic, Cleveland, OH, discusses findings from the TEMPO trials evaluating tavapadon, a selective dopamine D1/D5 receptor partial agonist, as monotherapy in early Parkinson disease and as an adjunct to levodopa in patients with motor fluctuations. He examines efficacy, tolerability, adverse events, and where tavapadon could fit within the evolving Parkinson disease treatment landscape.
Podden och tillhörande omslagsbild på den här sidan tillhör
Practical Neurology. Innehållet i podden är skapat av Practical Neurology och inte av,
eller tillsammans med, Poddtoppen.
